Fermion Oy

Executive Summary

Fermion Oy is a Finnish contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs) and drug products. As a fully integrated subsidiary of Orion Group, Fermion offers end-to-end services from drug substance to drug product manufacturing. Established in 2003 and headquartered in Espoo, Finland, the company markets all contract manufacturing services of the Orion Group. Fermion plays a critical role in the pharmaceutical supply chain by providing high-quality API manufacturing for both generic and innovative drugs. The company's expertise in small molecules and drug delivery positions it well within the growing CDMO market, which is benefiting from increased outsourcing by pharmaceutical companies. Despite being privately held with limited public financial disclosures, Fermion's affiliation with Orion provides stability and access to a broad client base. The company's strategic location in Finland offers advantages in terms of regulatory compliance and operational efficiency. Going forward, Fermion is expected to capitalize on the trend of pharmaceutical companies seeking reliable CDMO partners to manage complex manufacturing needs. However, competition from larger global CDMOs remains a challenge. Overall, Fermion is a well-positioned niche player in the API manufacturing space.

Upcoming Catalysts (preview)

• Q3 2026Expansion of API manufacturing capacity60% success
• TBDNew long-term contract wins with major pharma companies65% success
• Q4 2026Regulatory approval for new manufacturing facility50% success